Ozempic Boom: Hims & Eli Lilly Lead Healthcare Bets The race inside the weight loss industry is ramping up, leaving investors with three names to choose from in how they want to play this theme.
Is Beaten-Down Viking Therapeutics Stock a Buy on the Dip? A disappointing result for its oral obesity candidate hammered the stock price.
Here's Why Viking Therapeutics Bounced Back Today Viking's key drug demonstrated excellent body weight reduction data in a phase 2 trial, but its safety and tolerability data were disappointing.
Under Pressure: Palantir and Viking Therapeutics Face Investor Scrutiny The financial markets are a dynamic arena where fortunes can shift rapidly, and the past week has seen two prominent companies, Palantir Technologies Inc. (
NYSE: PLTR ) and Viking Therapeutics (
NASDAQ: VKTX ), come under intense investor scrutiny. Despite a year of impressive gains for Palantir, concerns over its valuation have led
Novo Nordisk Freezes Hiring As Wegovy Faces Copycats Novo Nordisk may pursue layoffs as its new CEO focuses on efficiency while facing intensifying obesity drug competition.
Is the Vanguard Dividend Appreciation ETF a Buy Now? This stalwart ETF offers a little bit of everything and could outperform the S&P 500 if the Magnificent Seven stocks tumble.
One of the Best Stocks to Buy Now? I ranked Eli Lilly as one of the best stocks to buy starting in 2025.
What's Going on With Eli Lilly Stock? The pharma company is gaining investor attention due to increasingly popular products.
Novo Nordisk Freezes Hiring To Cut Costs, Says Report: Retail Sees Stock Surpassing $100-Mark In A Year Novo’s website currently shows multiple job openings in the U.S. and mainland China, but merely eight open positions in Denmark.
Viking's 42% Plunge Splits Experts—A '$129 Strong Buy' Or 'Clearly Inferior' Drug? Viking (VKTX) stock plunged 42% after its obesity pill trial. Experts are split: some call it a $129 Strong Buy, others say it's inferior.
Viking Therapeutics Plummets as Oral Obesity Drug Trial Raises Tolerability Concerns San Diego, CA – Viking Therapeutics (
NASDAQ: VKTX ) experienced a dramatic stock decline today following the release of disappointing clinical trial results for its highly anticipated oral tablet designed to treat obesity and other metabolic disorders. The sharp downturn, which saw the company's shares plummet by over 30% in early trading,
Buy, Sell, or Hold? Insiders Pile Into These 3 Healthcare Stocks Insiders are buying stocks like LLY, TFX, and CALC. The question is whether they are also a good buy for investors, and not all of them are.
Viking Obesity Pill Faces Steep Climb Against Lilly's Tirzepatide, Analyst Calls Downtrend Reaction 'Extreme' Viking shares fell on Phase 2 obesity pill data as tolerability issues surfaced, but William Blair says the stock's sell-off is excessive.
Why Novo Nordisk Stock Popped Today For a cheap GLP-1 weight loss stock like Novo Nordisk, almost any news can help the stock pop.
Why Viking Therapeutics Stock Crashed Today Viking's new GLP-1 weight loss pill is pretty great -- but is it enough to turn the company profitable?
Eli Lilly Stock Investors Need to See This Competition among the makers of weight loss treatments is intensifying.
Like Eli Lilly, Viking Therapeutics' Oral Weight Loss Drug Disappoints, Stock Tanks Viking Therapeutics reported positive Phase 2 results for VK2735, showing significant weight loss and safety in obesity patients versus placebo.
Viking Therapeutics Crashes 35% On Mixed Results For Its Weight-Loss Pill Shares lost more than a third of their value after Viking unveiled mixed results for its oral VK2735.
Stock Market Today: S&P 500 Slips, Dow Futures Rise—Intel, Palo Alto, Home Depot In Focus U.S. stock futures were fluctuating on Tuesday following mostly unchanged moves from Monday. Futures of major benchmark indices were mixed.
GoodRx Holdings Surges 5% After Hours on Novo Nordisk Partnership for $499 Monthly Ozempic, Wegovy Access GoodRx stock rose 5.08% after it partnered with Novo Nordisk to offer Ozempic and Wegovy at a flat $499 monthly price for self-paying patients.
Ozempic And Wegovy Now Available Through GoodRx At Reduced Self-Pay Price, Stock Skyrockets GoodRx and Novo Nordisk launch a $499 monthly self-pay option for Ozempic and Wegovy, expanding access at 70,000 pharmacies across the U.S.
